Viewing 1 reply thread
  • Author
    Posts
    • #30116
      Steve Dragoo
      Participant

      Because of its simplicity and effectiveness, I trust this will move forward rapidly in human clinical trials but that means still years away for USA anyway.

      “Local delivery of BMP has been approved for clinical indications such as spinal fusion, but we were surprised and impressed that inhalation of recombinant BMP was able to effectively penetrate through the respiratory tract to instruct proper stem cell regeneration deep in the lung,” Peng said. “This demonstrates a potentially novel therapeutic route that appears to maximize treatment efficacy while lowering the toxicity profile for other organs that would be seen with an injectable or oral medication. This also presents a new therapeutic paradigm for lung fibrosis, where the goal is not just to stop the scarring, but also to stimulate native stem cells toward a regenerative program to restore healthy lung.”…

      https://www.ucsf.edu/news/2020/10/418766/inhalable-treatment-enhances-regeneration-lung-fibrosis-model?fbclid=IwAR1c3YIqAOcShpgZn-mGiZwRtq10RyPzny2I3iCjO0qZx9YC-cjzhaP9LVE

      Stay well,

      Steve

    • #32068
      George Poulsen
      Participant

      Steve, I started a reply in more detail, but I have more recently become quite interested in the Baraertib trials and their progress with mice due to my own development of IPF. In October of 2020 there was a published white paper on success to date and thoughts were that in a few years the human trials might progress since this is already an approved drug for Leukemia and is a collateral research for IPF. This is now a “few years later”.The publication was August 8, 2020, in the Journal EMBO Molecular Medicine. Co-responding authors were Rajesh Kasam, PH.D and Anil Goud Jegga, DVM.

      I have emailed the Cinncinati Childrens Hospital where the research team is apparently located, but have had no reply to-date.

      I’d really like to find a way to get on a news release or publication for that team to stay current, so anyone that might have that contributions regarding Barasertib progress would really help my own progress and expectations as well. So far a lot has been said on this drug and it makes for extremely interesting reading as you track it. Could be fun to stick around long enough to see it.

      • #32144
        Steve Dragoo
        Participant

        @ghpoulsen

        Hi George – most trials I have seen have news you can register for and if you request to be a standby that may get you more insight.

        Stay well…
        Steve

Viewing 1 reply thread
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account